by Heins Mills & Olson on January 20, 2015
We represent health and welfare fund plaintiffs and a proposed end-payor class of purchasers in this antitrust action alleging that defendants took anticompetitive steps to delay entry of lower-priced versions of prescription drugs (ACTOS and ACTOplus met), resulting in price overcharges to plaintiffs and the proposed class.